Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Brüggemann M[au]:

Search results

Items: 1 to 50 of 172

1.

Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS.

Knecht H, Reigl T, Kotrová M, Appelt F, Stewart P, Bystry V, Krejci A, Grioni A, Pal K, Stranska K, Plevova K, Rijntjes J, Songia S, Svatoň M, Froňková E, Bartram J, Scheijen B, Herrmann D, García-Sanz R, Hancock J, Moppett J, van Dongen JJM, Cazzaniga G, Davi F, Groenen PJTA, Hummel M, Macintyre EA, Stamatopoulos K, Trka J, Langerak AW, Gonzalez D, Pott C, Brüggemann M, Darzentas N; EuroClonality-NGS Working Group.

Leukemia. 2019 Jun 21. doi: 10.1038/s41375-019-0499-4. [Epub ahead of print]

PMID:
31227779
2.

Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS.

Scheijen B, Meijers RWJ, Rijntjes J, van der Klift MY, Möbs M, Steinhilber J, Reigl T, van den Brand M, Kotrová M, Ritter JM, Catherwood MA, Stamatopoulos K, Brüggemann M, Davi F, Darzentas N, Pott C, Fend F, Hummel M, Langerak AW, Groenen PJTA; EuroClonality-NGS Working Group.

Leukemia. 2019 Jun 13. doi: 10.1038/s41375-019-0508-7. [Epub ahead of print]

PMID:
31197258
3.

Scientific networks on Twitter: Analyzing scientists' interactions in the climate change debate.

Walter S, Lörcher I, Brüggemann M.

Public Underst Sci. 2019 Apr 26:963662519844131. doi: 10.1177/0963662519844131. [Epub ahead of print]

PMID:
31027461
4.

A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia.

Bassan R, Brüggemann M, Radcliffe HS, Hartfield E, Kreuzbauer G, Wetten S.

Haematologica. 2019 Mar 19. pii: haematol.2018.201053. doi: 10.3324/haematol.2018.201053. [Epub ahead of print]

5.

Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures.

Schroeder MP, Bastian L, Eckert C, Gökbuget N, James AR, Tanchez JO, Schlee C, Isaakidis K, Häupl B, Baum K, Migueles Lozano OA, Kouidri K, Pan KT, Urlaub H, Schwartz S, Burmeister T, von Stackelberg A, Hoelzer D, Pfeiffer H, Rieger MA, Göllner S, Oellerich T, Horstman M, Schrappe M, Wolf J, Kirschner-Schwabe R, Brüggemann M, Müller-Tidow C, Serve H, Neumann M, Baldus CD.

Sci Rep. 2019 Mar 12;9(1):4188. doi: 10.1038/s41598-019-40786-1.

6.

PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia.

Bastian L, Schroeder MP, Eckert C, Schlee C, Tanchez JO, Kämpf S, Wagner DL, Schulze V, Isaakidis K, Lázaro-Navarro J, Hänzelmann S, James AR, Ekici A, Burmeister T, Schwartz S, Schrappe M, Horstmann M, Vosberg S, Krebs S, Blum H, Hecht J, Greif PA, Rieger MA, Brüggemann M, Gökbuget N, Neumann M, Baldus CD.

Leukemia. 2019 Mar 6. doi: 10.1038/s41375-019-0430-z. [Epub ahead of print]

PMID:
30842609
7.

MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.

Pott C, Brüggemann M, Ritgen M, van der Velden VHJ, van Dongen JJM, Kneba M.

Methods Mol Biol. 2019;1956:199-228. doi: 10.1007/978-1-4939-9151-8_9.

PMID:
30779036
8.

Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia.

Gökbuget N, Dombret H, Giebel S, Bruggemann M, Doubek M, Foà R, Hoelzer D, Kim C, Martinelli G, Parovichnikova E, Rambaldi A, Ribera JM, Schoonen M, Stieglmaier JM, Zugmaier G, Bassan R.

Hematology. 2019 Dec;24(1):337-348. doi: 10.1080/16078454.2019.1567654.

9.

CD371 cell surface expression: A unique feature of DUX4-rearranged acute lymphoblastic leukemia.

Schinnerl D, Mejstrikova E, Schumich A, Zaliova M, Fortschegger K, Nebral K, Attarbaschi A, Fiser K, Kauer MO, Popitsch N, Haslinger S, Inthal A, Buldini B, Basso G, Bourquin JP, Gaipa G, Brüggemann M, Feuerstein T, Maurer-Granofszky M, Panzer-Grümayer R, Trka J, Mann G, Haas OA, Hrusak O, Dworzak MN, Strehl S.

Haematologica. 2019 Jan 31. pii: haematol.2018.214353. doi: 10.3324/haematol.2018.214353. [Epub ahead of print]

10.

Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies.

Clarke SC, Ma B, Trinklein ND, Schellenberger U, Osborn MJ, Ouisse LH, Boudreau A, Davison LM, Harris KE, Ugamraj HS, Balasubramani A, Dang KH, Jorgensen B, Ogana HAN, Pham DT, Pratap PP, Sankaran P, Anegon I, van Schooten WC, Brüggemann M, Buelow R, Force Aldred S.

Front Immunol. 2019 Jan 7;9:3037. doi: 10.3389/fimmu.2018.03037. eCollection 2018.

11.

Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia.

James AR, Schroeder MP, Neumann M, Bastian L, Eckert C, Gökbuget N, Tanchez JO, Schlee C, Isaakidis K, Schwartz S, Burmeister T, von Stackelberg A, Rieger MA, Göllner S, Horstman M, Schrappe M, Kirschner-Schwabe R, Brüggemann M, Müller-Tidow C, Serve H, Akalin A, Baldus CD.

J Hematol Oncol. 2019 Jan 14;12(1):8. doi: 10.1186/s13045-018-0692-3.

12.

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.

Langerak AW, Ritgen M, Goede V, Robrecht S, Bahlo J, Fischer K, Steurer M, Trněný M, Mulligan SP, Mey UJM, Trunzer K, Fingerle-Rowson G, Humphrey K, Stilgenbauer S, Böttcher S, Brüggemann M, Hallek M, Kneba M, van Dongen JJM.

Blood. 2019 Jan 31;133(5):494-497. doi: 10.1182/blood-2018-03-839688. Epub 2018 Nov 19. No abstract available.

13.

Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey.

Pigneux A, Montesinos P, Cong Z, Zhang X, Pownell AK, Wieffer H, McKendrick J, Brüggemann M.

BMC Cancer. 2018 Nov 12;18(1):1100. doi: 10.1186/s12885-018-5002-5.

14.

Next-generation amplicon TRB locus sequencing can overcome limitations of flow-cytometric Vβ expression analysis and confirms clonality in all T-cell prolymphocytic leukemia cases.

Kotrova M, Novakova M, Oberbeck S, Mayer P, Schrader A, Knecht H, Hrusak O, Herling M, Brüggemann M.

Cytometry A. 2018 Nov;93(11):1118-1124. doi: 10.1002/cyto.a.23604. Epub 2018 Nov 10.

PMID:
30414304
15.

Skin involvement by chronic lymphocytic leukaemia is frequently associated with unrelated neoplastic or inflammatory cutaneous disease and is not indicative of general disease progression.

Thiesen I, Wehkamp U, Brüggemann M, Ritgen M, Murga Penas EM, Klapper W, Oschlies I.

Br J Dermatol. 2019 Jan;180(1):227-228. doi: 10.1111/bjd.17135. Epub 2018 Oct 25. No abstract available.

PMID:
30183072
16.

Author Correction: Interfacial photochemistry at the ocean surface is a global source of organic vapors and aerosols.

Brüggemann M, Hayeck N, George C.

Nat Commun. 2018 Aug 8;9(1):3222. doi: 10.1038/s41467-018-05687-3.

17.

Interfacial photochemistry at the ocean surface is a global source of organic vapors and aerosols.

Brüggemann M, Hayeck N, George C.

Nat Commun. 2018 May 29;9(1):2101. doi: 10.1038/s41467-018-04528-7. Erratum in: Nat Commun. 2018 Aug 8;9(1):3222.

18.

Sequence-Based Discovery Demonstrates That Fixed Light Chain Human Transgenic Rats Produce a Diverse Repertoire of Antigen-Specific Antibodies.

Harris KE, Aldred SF, Davison LM, Ogana HAN, Boudreau A, Brüggemann M, Osborn M, Ma B, Buelow B, Clarke SC, Dang KH, Iyer S, Jorgensen B, Pham DT, Pratap PP, Rangaswamy US, Schellenberger U, van Schooten WC, Ugamraj HS, Vafa O, Buelow R, Trinklein ND.

Front Immunol. 2018 Apr 24;9:889. doi: 10.3389/fimmu.2018.00889. eCollection 2018.

19.

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.

Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC.

Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22. Erratum in: Blood. 2019 Jun 13;133(24):2625.

20.

Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation.

Pfeifer H, Raum K, Markovic S, Nowak V, Fey S, Obländer J, Pressler J, Böhm V, Brüggemann M, Wunderle L, Hüttmann A, Wäsch R, Beck J, Stelljes M, Viardot A, Lang F, Hoelzer D, Hofmann WK, Serve H, Weiss C, Goekbuget N, Ottmann OG, Nowak D.

Blood. 2018 Mar 29;131(13):1464-1475. doi: 10.1182/blood-2017-07-796862. Epub 2018 Jan 18.

21.

Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation.

Brüggemann M, Kotrova M.

Blood Adv. 2017 Nov 28;1(25):2456-2466. doi: 10.1182/bloodadvances.2017009845. eCollection 2017 Nov 28. Review.

22.

Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation.

Brüggemann M, Kotrova M.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):13-21. doi: 10.1182/asheducation-2017.1.13. Review.

23.

Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia.

Lhermitte L, Mejstrikova E, van der Sluijs-Gelling AJ, Grigore GE, Sedek L, Bras AE, Gaipa G, Sobral da Costa E, Novakova M, Sonneveld E, Buracchi C, de Sá Bacelar T, Te Marvelde JG, Trinquand A, Asnafi V, Szczepanski T, Matarraz S, Lopez A, Vidriales B, Bulsa J, Hrusak O, Kalina T, Lecrevisse Q, Martin Ayuso M, Brüggemann M, Verde J, Fernandez P, Burgos L, Paiva B, Pedreira CE, van Dongen JJM, Orfao A, van der Velden VHJ.

Leukemia. 2018 Apr;32(4):874-881. doi: 10.1038/leu.2017.313. Epub 2017 Nov 1.

24.

Knotting nets: Molecular junctions of interconnecting endocrine axes identified by application of the adverse outcome pathway concept.

Brüggemann M, Licht O, Fetter É, Teigeler M, Schäfers C, Eilebrecht E.

Environ Toxicol Chem. 2018 Feb;37(2):318-328. doi: 10.1002/etc.3995. Epub 2017 Dec 13. Review.

PMID:
28984380
25.

Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy.

Nagel I, Bartels M, Duell J, Oberg HH, Ussat S, Bruckmueller H, Ottmann O, Pfeifer H, Trautmann H, Gökbuget N, Caliebe A, Kabelitz D, Kneba M, Horst HA, Hoelzer D, Topp MS, Cascorbi I, Siebert R, Brüggemann M.

Blood. 2017 Nov 2;130(18):2027-2031. doi: 10.1182/blood-2017-05-782888. Epub 2017 Aug 21.

26.

Atmospheric chemistry and the biosphere: general discussion.

Archibald A, Arnold S, Bejan L, Brown S, Brüggemann M, Carpenter LJ, Collins W, Evans M, Finlayson-Pitts B, George C, Hastings M, Heard D, Hewitt CN, Isaacman-VanWertz G, Kalberer M, Keutsch F, Kiendler-Scharr A, Knopf D, Lelieveld J, Marais E, Petzold A, Ravishankara A, Reid J, Rovelli G, Scott C, Sherwen T, Shindell D, Tinel L, Unger N, Wahner A, Wallington TJ, Williams J, Young P, Zelenyuk A.

Faraday Discuss. 2017 Aug 24;200:195-228. doi: 10.1039/c7fd90038d. No abstract available.

PMID:
28795727
27.

Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia.

Kobitzsch B, Gökbuget N, Schwartz S, Reinhardt R, Brüggemann M, Viardot A, Wäsch R, Starck M, Thiel E, Hoelzer D, Burmeister T.

Haematologica. 2017 Oct;102(10):1739-1747. doi: 10.3324/haematol.2016.161273. Epub 2017 Jul 27.

28.

Systematic Analysis of the Expression of the Mitochondrial ATP Synthase (Complex V) Subunits in Clear Cell Renal Cell Carcinoma.

Brüggemann M, Gromes A, Poss M, Schmidt D, Klümper N, Tolkach Y, Dietrich D, Kristiansen G, Müller SC, Ellinger J.

Transl Oncol. 2017 Aug;10(4):661-668. doi: 10.1016/j.tranon.2017.06.002. Epub 2017 Jun 30.

29.

Interfacial photochemistry of biogenic surfactants: a major source of abiotic volatile organic compounds.

Brüggemann M, Hayeck N, Bonnineau C, Pesce S, Alpert PA, Perrier S, Zuth C, Hoffmann T, Chen J, George C.

Faraday Discuss. 2017 Aug 24;200:59-74. doi: 10.1039/c7fd00022g.

PMID:
28598469
30.

Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?

Kotrova M, Trka J, Kneba M, Brüggemann M.

Mol Diagn Ther. 2017 Oct;21(5):481-492. doi: 10.1007/s40291-017-0277-9. Review.

PMID:
28452038
31.

High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges.

Langerak AW, Brüggemann M, Davi F, Darzentas N, van Dongen JJM, Gonzalez D, Cazzaniga G, Giudicelli V, Lefranc MP, Giraud M, Macintyre EA, Hummel M, Pott C, Groenen PJTA, Stamatopoulos K; EuroClonality-NGS Consortium.

J Immunol. 2017 May 15;198(10):3765-3774. doi: 10.4049/jimmunol.1602050. Epub 2017 Apr 17.

32.

GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses.

Sellner L, Brüggemann M, Schlitt M, Knecht H, Herrmann D, Reigl T, Krejci A, Bystry V, Darzentas N, Rieger M, Dietrich S, Luft T, Ho AD, Kneba M, Dreger P.

Bone Marrow Transplant. 2017 Apr;52(4):656. doi: 10.1038/bmt.2017.12. No abstract available.

PMID:
28377595
33.

Lot-to-lot stability of antibody reagents for flow cytometry.

Böttcher S, van der Velden VHJ, Villamor N, Ritgen M, Flores-Montero J, Murua Escobar H, Kalina T, Brüggemann M, Grigore G, Martin-Ayuso M, Lecrevisse Q, Pedreira CE, van Dongen JJM, Orfao A.

J Immunol Methods. 2017 Mar 30. pii: S0022-1759(17)30075-3. doi: 10.1016/j.jim.2017.03.018. [Epub ahead of print]

PMID:
28365329
34.

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS.

N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783.

35.

Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL.

Kotrova M, van der Velden VHJ, van Dongen JJM, Formankova R, Sedlacek P, Brüggemann M, Zuna J, Stary J, Trka J, Fronkova E.

Bone Marrow Transplant. 2017 Jul;52(7):962-968. doi: 10.1038/bmt.2017.16. Epub 2017 Feb 27.

PMID:
28244980
36.

Strategies to Obtain Diverse and Specific Human Monoclonal Antibodies From Transgenic Animals.

Brüggemann M, Osborn MJ, Ma B, Buelow R.

Transplantation. 2017 Aug;101(8):1770-1776. doi: 10.1097/TP.0000000000001702. Review.

PMID:
28230642
37.

ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data.

Bystry V, Reigl T, Krejci A, Demko M, Hanakova B, Grioni A, Knecht H, Schlitt M, Dreger P, Sellner L, Herrmann D, Pingeon M, Boudjoghra M, Rijntjes J, Pott C, Langerak AW, Groenen PJTA, Davi F, Brüggemann M, Darzentas N; EuroClonality-NGS.

Bioinformatics. 2017 Feb 1;33(3):435-437. doi: 10.1093/bioinformatics/btw634.

PMID:
28172348
38.

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.

Gökbuget N, Zugmaier G, Klinger M, Kufer P, Stelljes M, Viardot A, Horst HA, Neumann S, Brüggemann M, Ottmann OG, Burmeister T, Wessiepe D, Topp MS, Bargou R.

Haematologica. 2017 Apr;102(4):e132-e135. doi: 10.3324/haematol.2016.153957. Epub 2017 Jan 12. No abstract available.

39.

Antigen-specific single B cell sorting and expression-cloning from immunoglobulin humanized rats: a rapid and versatile method for the generation of high affinity and discriminative human monoclonal antibodies.

Ouisse LH, Gautreau-Rolland L, Devilder MC, Osborn M, Moyon M, Visentin J, Halary F, Bruggemann M, Buelow R, Anegon I, Saulquin X.

BMC Biotechnol. 2017 Jan 9;17(1):3. doi: 10.1186/s12896-016-0322-5.

40.

Systematic Expression Analysis of Mitochondrial Complex I Identifies NDUFS1 as a Biomarker in Clear-Cell Renal-Cell Carcinoma.

Ellinger J, Poss M, Brüggemann M, Gromes A, Schmidt D, Ellinger N, Tolkach Y, Dietrich D, Kristiansen G, Müller SC.

Clin Genitourin Cancer. 2017 Aug;15(4):e551-e562. doi: 10.1016/j.clgc.2016.11.010. Epub 2016 Dec 1.

PMID:
28063846
41.

GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses.

Sellner L, Brüggemann M, Schlitt M, Knecht H, Herrmann D, Reigl T, Krejci A, Bystry V, Darzentas N, Rieger M, Dietrich S, Luft T, Ho AD, Kneba M, Dreger P.

Bone Marrow Transplant. 2017 Apr;52(4):544-551. doi: 10.1038/bmt.2016.305. Epub 2016 Dec 12. Erratum in: Bone Marrow Transplant. 2017 Apr;52(4):656.

PMID:
27941777
42.

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.

Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, Gaipa G, Bartels M, Sobral da Costa E, Kotrová M, Novakova M, Sonneveld E, Buracchi C, Bonaccorso P, Oliveira E, Te Marvelde JG, Szczepanski T, Lhermitte L, Hrusak O, Lecrevisse Q, Grigore GE, Froňková E, Trka J, Brüggemann M, Orfao A, van Dongen JJ, van der Velden VH; EuroFlow Consortium.

Blood. 2017 Jan 19;129(3):347-357. doi: 10.1182/blood-2016-07-726307. Epub 2016 Nov 30.

43.

Comprehensive translocation and clonality detection in lymphoproliferative disorders by next-generation sequencing.

Wren D, Walker BA, Brüggemann M, Catherwood MA, Pott C, Stamatopoulos K, Langerak AW, Gonzalez D; EuroClonality-NGS consortium.

Haematologica. 2017 Feb;102(2):e57-e60. doi: 10.3324/haematol.2016.155424. Epub 2016 Oct 20. No abstract available.

44.

Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma.

Ellinger J, Gromes A, Poss M, Brüggemann M, Schmidt D, Ellinger N, Tolkach Y, Dietrich D, Kristiansen G, Müller SC.

Oncotarget. 2016 Dec 27;7(52):86490-86499. doi: 10.18632/oncotarget.13275.

45.

Epileptic seizures and rhinocerebral mucormycosis during blinatumomab treatment in a patient with biphenotypic acute leukemia.

Vogt N, Heß K, Bialek R, Buerke B, Brüggemann M, Topp MS, Groth C, Berdel WE, Lenz G, Stelljes M.

Ann Hematol. 2017 Jan;96(1):151-153. doi: 10.1007/s00277-016-2837-1. Epub 2016 Oct 3. No abstract available.

PMID:
27696204
46.

Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis.

Herold T, Schneider S, Metzeler KH, Neumann M, Hartmann L, Roberts KG, Konstandin NP, Greif PA, Bräundl K, Ksienzyk B, Huk N, Schneider I, Zellmeier E, Jurinovic V, Mansmann U, Hiddemann W, Mullighan CG, Bohlander SK, Spiekermann K, Hoelzer D, Brüggemann M, Baldus CD, Dreyling M, Gökbuget N.

Haematologica. 2017 Jan;102(1):130-138. doi: 10.3324/haematol.2015.136366. Epub 2016 Aug 25.

47.

Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M.

Oncoimmunology. 2015 Jun 5;5(1):e1058459. eCollection 2016.

48.

Critical assessment of ionization patterns and applications of ambient desorption/ionization mass spectrometry using FAPA-MS.

Brüggemann M, Karu E, Hoffmann T.

J Mass Spectrom. 2016 Feb;51(2):141-9. doi: 10.1002/jms.3733.

PMID:
26889930
49.

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.

Zugmaier G, Gökbuget N, Klinger M, Viardot A, Stelljes M, Neumann S, Horst HA, Marks R, Faul C, Diedrich H, Reichle A, Brüggemann M, Holland C, Schmidt M, Einsele H, Bargou RC, Topp MS.

Blood. 2015 Dec 10;126(24):2578-84. doi: 10.1182/blood-2015-06-649111. Epub 2015 Oct 19.

50.

The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL.

Kotrova M, Muzikova K, Mejstrikova E, Novakova M, Bakardjieva-Mihaylova V, Fiser K, Stuchly J, Giraud M, Salson M, Pott C, Brüggemann M, Füllgrabe M, Stary J, Trka J, Fronkova E.

Blood. 2015 Aug 20;126(8):1045-7. doi: 10.1182/blood-2015-07-655159. No abstract available.

Supplemental Content

Loading ...
Support Center